We have also shown that ex vivo IFNγ treatment enhanced in a BCL6-dependent manner the cluster formation of imatinib-treated primary human CD34+ CML stem/progenitor cells. The gene discussed is IFNG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.